Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer?

Nature Clinical Practice Nephrology volume 3, pages 418–419 (2007)Cite this article

boxed-textWhite CA et al. (2007) Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 71: 312–317

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245–252

    Article  CAS  Google Scholar 

  2. Block GA et al. (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815–1824

    Article  CAS  Google Scholar 

  3. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3) : S1–S201

  4. Manns B et al. (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239–1247

    Article  CAS  Google Scholar 

  5. Block GA et al. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438–441

    Article  CAS  Google Scholar 

  6. Suki W et al. (2005) A prospective randomized trial assessing the impact on outcomes of sevelamer in dialysis patients [abstract]. J Am Soc Nephrol 16: 281A

    Google Scholar 

  7. Garside R et al. (2007) The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 22: 1428–1436

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. and M Fukagawa is Associate Professor and Director of the Division of Nephrology and Kidney Center, H Komaba is a Staff Nephrologist and Medical Graduate, at Kobe University School of Medicine, Kobe, Japan.,

    Hirotaka Komaba & Masafumi Fukagawa

Authors
  1. Hirotaka Komaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masafumi Fukagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masafumi Fukagawa.

Ethics declarations

Competing interests

The authors have received research support from Chugai and Kirin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Komaba, H., Fukagawa, M. Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer?. Nat Rev Nephrol 3, 418–419 (2007). https://doi.org/10.1038/ncpneph0536

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0536

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing